Pfizer Inc. has announced that Jeffrey Legos, PhD, MBA, will join the company as Chief Oncology Officer. In this role, Dr.
Legos holds a PhD in physiology from Temple University and an MBA in finance from Villanova University. He has also written over 40 manuscripts and abstracts for peer-reviewed journals. Further, he ...
A man of many layers Winterwatch presenter Chris Packham says that viewers write in to complain that he is wearing too much on screen. ‘Some viewers question why we have so much winter gear on.
After promoting its oncology officer Chris Boshoff to chief scientific officer last fall, Pfizer has found his successor.
Pfizer is laying down new pieces for its leadership ... Chief Oncology Officer and Executive Vice President Chris Boshoff, M.D., Ph.D., took on Dolsten’s position at the start of 2025, with ...
The pharmaceutical giant named Jeffrey Legos the head of a division it is counting on to overcome investor pressure and grow sales in the years ahead.
Trump's FDA pick is surgeon and writer Martin Makary November 23, 2024 Pfizer said on Wednesday it has named company veteran and oncology head Chris Boshoff as its chief of research and ...
Dr Legos will report to Dr Chris Boshoff, chief scientific officer and president, Pfizer R&D, and will represent oncology on Pfizer’s R&D leadership team. Dr Legos will succeed Dr Roger Dansey, who ...
2025 Expected Net Savings from Cost Realignment: $4.5 billion by the end of 2025. Pfizer Inc (NYSE:PFE) successfully integrated the Seagen business, enhancing its oncology capabilities.
2025 Expected Net Savings from Cost Realignment: $4.5 billion by the end of 2025. Pfizer Inc (NYSE:PFE) successfully integrated the Seagen business, enhancing its oncology capabilities. The company ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback